Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Potassium voltage-gated channel modifier subfamily G member 1 (KCNG1)
- Target
- KCNG1
- Molecular classification
- Ion channel, Voltage-gated potassium channel regulatory subunit
01
Overview
Potassium voltage-gated channel modifier subfamily G member 1 (KCNG1) is a regulatory alpha-subunit of the voltage-gated potassium (Kv) channel, notably within the Kv6.1 designation. KCNG1 does not form functional potassium channels by itself, but modulates the expression and functional properties of other Kv channels, such as KCNB1 (Kv2.1) or KCNB2, when co-assembled with them. It influences the channels’ kinetics, deactivation, and inactivation properties, especially in contexts of repolarization and sustained depolarization. KCNG1 is highly expressed in skeletal muscle and is present in several tissues, with possible alternative splicing generating distinct isoforms. Its biological roles include regulating excitability in neurons, contracting muscles, and maintaining proper potassium ion flux required for normal physiological function. Disease associations are limited but include autism spectrum disorder and coumarin resistance. No selective drugs or biomarkers are currently available for KCNG1 modulation.
- Other names
- Kv6.1kH2K13KCNGvoltage-gated potassium channel subunit Kv6.1potassium channel KH2potassium channel Kv6.1potassium channel, voltage-gated modifier subfamily G member 1
02
Mechanism of action
Not applicable—no known drugs with direct, selective mechanism of action against KCNG1.
03
Biological functions
Regulation of membrane potentialModulation of neuronal excitabilityRegulation of neurotransmitter releaseModulation of heart rateRegulation of insulin secretionSmooth muscle contractionEpithelial electrolyte transportCell volume regulation
04
Disease associations
Autism spectrum disorderCoumarin resistancePotential involvement in other neuronal and muscular disorders (based on biological role; explicit evidence limited)
05
Safety considerations
Modulation of potassium channels can lead to altered cardiac and neuronal function; theoretical safety concerns in arrhythmia or neuroexcitability, but no KCNG1-specific issues noted in clinical data
Beyond the preview
Go deeper on Potassium voltage-gated channel modifier subfamily G member 1 (KCNG1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Potassium voltage-gated channel modifier subfamily G member 1 (KCNG1).